Compare NVCR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVCR | VERA |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2015 | 2021 |
| Metric | NVCR | VERA |
|---|---|---|
| Price | $12.81 | $51.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $28.42 | ★ $76.60 |
| AVG Volume (30 Days) | 1.9M | ★ 1.9M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $642,269,000.00 | N/A |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $10.70 | $18.53 |
| 52 Week High | $32.06 | $51.72 |
| Indicator | NVCR | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 78.40 |
| Support Level | $12.30 | $47.22 |
| Resistance Level | $13.94 | $51.19 |
| Average True Range (ATR) | 0.60 | 3.55 |
| MACD | 0.05 | 0.54 |
| Stochastic Oscillator | 64.92 | 97.47 |
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.